DE:NP5 Stock Latest News
Company AnnouncementsNewron Completes Enrollment in Pivotal Phase 3 Schizophrenia Study1w ago
Company AnnouncementsNewron presses on with Evenamide Phase 3 as FDA halts U.S. arm over safety signal3w ago
Company AnnouncementsNewron presses on with ENIGMA-TRS program as FDA clinical hold prompts safety review3w ago
Company AnnouncementsNewron Faces Ongoing FDA Hold on U.S. Arm of Key Evenamide Schizophrenia Trial1M agoCompany AnnouncementsNewron Bolsters Finances as Evenamide Phase 3 Program Advances Toward 2027 Readouts1M ago
Company AnnouncementsNewron Ramps Up Evenamide Phase 3 as Financing and Patent Wins Offset Wider Loss1M ago
- Company AnnouncementsNewron secures EUR 5.5 million tranche to fund Phase 3 Evenamide program1M ago
Company AnnouncementsNewron Bolsters Phase 3 Schizophrenia Program with EUR 5.5 Million Share Subscription1M ago- Company AnnouncementsNewron completes pivotal Phase 3 recruitment for Evenamide in treatment-resistant schizophrenia2M ago
Company AnnouncementsNewron Advances Pivotal Phase 3 Trial of Schizophrenia Candidate Evenamide2M ago
Company AnnouncementsNewron, FDA in constructive talks over U.S. trial halt for schizophrenia drug Evenamide4M ago
Company AnnouncementsFDA halts U.S. recruitment in Newron’s key schizophrenia trial after patient death6M ago
- Company AnnouncementsNewron Shareholders Back Board Changes at 2026 General Meeting6M ago
Company AnnouncementsNewron Pharmaceuticals’ Earnings Call Signals Pivotal Year Ahead7M ago
Company AnnouncementsNewron bolsters finances as Evenamide enters pivotal global Phase III7M ago
Company AnnouncementsNewron Fortifies Evenamide Phase III Push with Fresh Capital, Patent Win and Board Overhaul7M agoCompany AnnouncementsNewron to Highlight Phase III Evenamide Data at 2026 Schizophrenia Congress7M ago
Company AnnouncementsNewron extends EIB loan maturities to align financing with Evenamide milestones7M ago
